Literature DB >> 26600929

Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features.

Yves Dittmar1, Utz Settmacher1.   

Abstract

Gastric cancer is one of the most common malignancies worldwide. The overall prognosis remains poor over the last decades even though improvements in surgical outcomes have been achieved. A better understanding of the molecular biology of gastric cancer and detection of eligible molecular targets might be of central interest to further improve clinical outcome. With this intention, first steps have been made in the research of growth factor signaling. Regarding morphogens, cell cycle and nuclear factor-κB signaling, a remarkable count of target-specific agents have been developed, nevertheless the transfer into the field of clinical routine is still at the beginning. The potential utility of epigenetic targets and the further evaluation of microRNA signaling seem to have potential for the development of novel treatment strategies in the future.

Entities:  

Keywords:  Gastric cancer; Molecular biology; Personalized medicine; Signaling pathway; Targeted therapy

Year:  2015        PMID: 26600929      PMCID: PMC4644852          DOI: 10.4251/wjgo.v7.i11.292

Source DB:  PubMed          Journal:  World J Gastrointest Oncol


  81 in total

1.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Authors:  Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart
Journal:  Lancet       Date:  2007-01-06       Impact factor: 79.321

Review 2.  The Notch signaling pathway: transcriptional regulation at Notch target genes.

Authors:  T Borggrefe; F Oswald
Journal:  Cell Mol Life Sci       Date:  2009-05       Impact factor: 9.261

3.  Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation.

Authors:  Roberta Caruso; Francesco Pallone; Daniele Fina; Valentina Gioia; Ilaria Peluso; Flavio Caprioli; Carmine Stolfi; Alessandra Perfetti; Luigi Giusto Spagnoli; Giampiero Palmieri; Thomas T Macdonald; Giovanni Monteleone
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

Review 4.  The history and future of targeting cyclin-dependent kinases in cancer therapy.

Authors:  Uzma Asghar; Agnieszka K Witkiewicz; Nicholas C Turner; Erik S Knudsen
Journal:  Nat Rev Drug Discov       Date:  2015-02       Impact factor: 84.694

5.  Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06).

Authors:  Thomas Ruhstaller; Miklos Pless; Daniel Dietrich; Helmut Kranzbuehler; Roger von Moos; Peter Moosmann; Michael Montemurro; Paul M Schneider; Daniel Rauch; Oliver Gautschi; Walter Mingrone; Lucas Widmer; Roman Inauen; Peter Brauchli; Viviane Hess
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

6.  Transforming growth factor-beta signaling in stem cells and cancer.

Authors:  Lopa Mishra; Rik Derynck; Bibhuti Mishra
Journal:  Science       Date:  2005-10-07       Impact factor: 47.728

7.  Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.

Authors:  Kristine S Klos; Xiaoyan Zhou; Sangkyou Lee; Lianglin Zhang; Wentao Yang; Yoichi Nagata; Dihua Yu
Journal:  Cancer       Date:  2003-10-01       Impact factor: 6.860

Review 8.  Palliative management of gastric cancer.

Authors:  Steven C Cunningham; Richard D Schulick
Journal:  Surg Oncol       Date:  2007-09-18       Impact factor: 3.279

Review 9.  Targeting the PDGF signaling pathway in tumor treatment.

Authors:  Carl-Henrik Heldin
Journal:  Cell Commun Signal       Date:  2013-12-20       Impact factor: 5.712

10.  The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis.

Authors:  Steven R Whittaker; Robert H Te Poele; Florence Chan; Spiros Linardopoulos; Michael I Walton; Michelle D Garrett; Paul Workman
Journal:  Cell Cycle       Date:  2007-10-05       Impact factor: 4.534

View more
  6 in total

Review 1.  Ongoing surgical clinical trials on minimally invasive surgery for gastric cancer: Korea.

Authors:  Ju-Hee Lee
Journal:  Transl Gastroenterol Hepatol       Date:  2016-05-18

2.  The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients.

Authors:  Minghui Zhang; Yuandi Dong; Haitao Liu; Yan Wang; Shu Zhao; Qijia Xuan; Yan Wang; Qingyuan Zhang
Journal:  Sci Rep       Date:  2016-11-28       Impact factor: 4.379

3.  Prognostic implications of HER2 heterogeneity in gastric cancer.

Authors:  Shigenobu Motoshima; Koji Yonemoto; Hideki Kamei; Michi Morita; Rin Yamaguchi
Journal:  Oncotarget       Date:  2018-01-18

4.  Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis.

Authors:  Li Yang; Xian-Zhe Dong; Xiao-Xuan Xing; Xiao-Hui Cui; Lin Li; Lan Zhang
Journal:  World J Gastrointest Oncol       Date:  2020-11-15

5.  Importance of Mevalonate Pathway Lipids on the Growth and Survival of Primary and Metastatic Gastric Carcinoma Cells.

Authors:  Natalia Ortiz; Juan Carlos Delgado-Carazo; Cecilia Díaz
Journal:  Clin Exp Gastroenterol       Date:  2021-05-31

6.  PFK15, a Small Molecule Inhibitor of PFKFB3, Induces Cell Cycle Arrest, Apoptosis and Inhibits Invasion in Gastric Cancer.

Authors:  Wei Zhu; Liang Ye; Jianzhao Zhang; Pengfei Yu; Hongbo Wang; Zuguang Ye; Jingwei Tian
Journal:  PLoS One       Date:  2016-09-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.